LA JOLLA, CA—New research led by scientists at La Jolla Institute for Immunology (LJI) reveals the workings of a human ...

Plus: A shift in bird flu strategy, a new vaccine for meningococcal disease, a new AI genomics model from Nvidia and more.

Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu SHELTON, CT / ACCESS Newswire / February 19, 2025 / NanoViricides, Inc. (the ...

SHELTON, CT / ACCESS Newswire / February 11, 2025 / NanoViricides, Inc. (the "Company") declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum antiviral drug ...

A federal judge said the Trump administration’s deferred resignation program for federal workers could move forward, allowing the White House to advance a critical part of its plan to reduce the ...

Jan. 2, 2025 — A new study uncovers how a novel immunotherapy prevents squamous cell carcinoma, with benefits lasting five years after treatment. This therapy is ... Study Traces Ebola's Route ...

The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant ...

Is the Sudan virus deadlier than Ebola? A key discovery explains how it clings to human cells. The Sudan virus, a close relative of Ebola, has a 50% fatality rate, but its mechanisms of cell ...

A better understanding of inflammation and lung immunity over the past two decades has led to new, innovative treatments for ...

The Sudan virus, a close relative of Ebola, has a fatality rate of 50% but remains poorly understood in terms of how it infects cells. Currently, no approved treatments exist. To address this critical ...